Other name:ATL-962,Cetilistat (ATL-962),New alistat,"Oblean"
CAS: 282526-98-1
Molecular Formula:C25H39NO3
MolecularWeight::401.58
Source: Synthetic
Appearance: White to off white powder
Assay :≥99.0%
Heavy metals: <10PPM
Cetilistat also known as Cetilistat (ATL-962) and Cetislim, is a new gastrointestinal lipase inhibitor developed by the British company Alizyme, and later "NorginaBV" has won the global agency of "cetiristone Chemicalbook". Cetirista is conducting a phase 3 clinical trial in the United States. In Japan, in cooperation with Takeda Pharmaceuticals, neolilitar was approved as a drug for the treatment of obesity in September 2013. The name of the product is "Oblean".
Itis a new pancreatic lipase inhibitor for the treatment of obesity in diabetic and non-diabetic patients.